Physician profile
Jay B Stallman
NPI 1457354607
$41,611.77
in general payments reported to CMS, 2019-2025
24 companies · $921 in 2025
The $921 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,679 · 2020: $3,341 · 2021: $15K · 2022: $12K · 2023: $3,255 · 2024: $1,469 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,175 · Consulting Fee: $1,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,175.04 |
| Consulting Fee | $1,470.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $28,867.78 | 2019-2022 | |
| Alcon Vision LLC | $2,620.61 | 2019-2023 | |
| Alimera Sciences, INC. | $2,200.40 | 2019-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $1,708.97 | 2019-2025 | Vabysmo, Lucentis |
| Regeneron Healthcare Solutions, INC. | $1,320.28 | 2019-2025 | Eylea, Eylea Hd |
| Apellis Pharmaceuticals, INC. | $843.76 | 2022-2025 | Syfovre |
| Astellas Pharma US INC | $539.75 | 2023-2025 | Izervay |
| Eyepoint US, INC. | $441.13 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $411.27 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $392.66 | 2024-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Carl Zeiss Meditec USA, INC. | $381.32 | 2021-2022 | |
| Abbvie INC. | $337.05 | 2022-2025 | Ozurdex |
| Bausch & Lomb Americas INC. | $308.67 | 2024 | Xipere, Visudyne |
| Allergan, INC. | $239.58 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $143.06 | 2023 | Eylea |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $136.91 | 2024 | Tepezza |
| Genentech, INC. | $126.88 | 2021 | |
| Dutch Ophthalmic, USA | $126.78 | 2019 | |
| Rxsight INC | $124.95 | 2022 | |
| Samsara Vision | $114.36 | 2025 | Implantable Miniature Telescope (Imt By Dr. Isaac Lipshitz) |
| Notal Vision, INC. | $92.66 | 2019 | |
| Coherus Oncology, INC. | $77.89 | 2022-2023 | |
| Sandoz INC. | $38.39 | 2024 | Cimerli |
| Mallinckrodt Hospital Products INC. | $16.66 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$441,366.78 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Stallman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.